{
    "nct_id": "NCT04861064",
    "official_title": "Weekly Sirolimus Therapy for the Treatment of Venous and Lymphatic Malformations",
    "inclusion_criteria": "* Patient 2 years of age and older\n* Venous, lymphatic, or venolymphatic malformations\nHealthy volunteers allowed\nMust have minimum age of 2 Years",
    "exclusion_criteria": "* Children with contraindication to use of sirolimus\n* Children with history of transplant\n* Children with a history of natural immunodeficiency\n* Children with a history of artificially induced immunodeficiency\n* Children with a history of a serious or life-threatening infection\n* Children taking CYP3A4 inhibiting medications\n* Children taking strong CYP3A4 inducers to avoid subtherapeutic dosing/exposure.\n* Inability or unwillingness of subject or legal guardian/representative to give informed consent\n* Women that are or may become pregnant o Sirolimus is a Pregnancy Category C drug. No randomized controlled studies have been done on pregnant women. Women of childbearing potential must be on effective contraception prior to, during, and for 12 weeks following sirolimus therapy.",
    "miscellaneous_criteria": ""
}